Business
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
The Trianni Mouse®, AbCellera’s technology for generating large databases of human antibodies for drug discovery programs, is granted United States patent
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\nThe Trianni Mouse®, AbCellera’s technology for generating large databases of human antibodies for drug discovery programs, is granted United States patent\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug discovery programs with biotech and pharma partners. The United States Patent and Trademark Office (USPTO) issued patent no. 10,881,084 titled “Transgenic Animals and Methods of Use” to Trianni, Inc. (Trianni), an AbCellera Company.\n\n“This patent is an important addition to our IP portfolio, providing protection to our proprietary technology in the U.S.,” said Carl Hansen, Ph.D., CEO of AbCellera and Trianni. “By generating fully human antibodies in the first step of the discovery process, we’re able to increase the speed and efficiency of our partners’ programs to develop therapeutic antibodies.”\n\nTrianni’s genetic engineering technology, which AbCellera acquired in November 2020, is an advanced transgenic platform for developing mice that produce human antibodies. The flagship Trianni Mouse® platform was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies. It is also a core platform for quickly developing increasingly powerful transgenic mouse technologies for use in partner programs.\n\nAbout AbCellera Biologics Inc.\n\nAbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.\n\nAbout Trianni, Inc.\n\nTrianni, an AbCellera company, specializes in antibody discovery technology using transgenic mice. Trianni’s lead technology, the Trianni Mouse®, is a next-generation platform enabling efficient generation of diverse, ful...